Earnings Feed
Start Free
Home/Filings/4/0001209191-21-056519
4//SEC Filing

Judice Kevin 4

Accession 0001209191-21-056519

CIK 0001645569other
View on SEC.govCompany Profile

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 9:18 PM ET

Size

18.3 KB

Accession

0001209191-21-056519

Insider Transaction Report

Form 4
Period: 2021-09-14
DICE Therapeutics, Inc.DICE
Judice Kevin
DirectorCEO
Transactions
  • Award

    Stock Option (right to buy)

    2021-09-14+20,464→ 20,464 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (20,464 underlying)
  • Award

    Stock Option (right to buy)

    2021-09-14+16,661→ 16,661 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (16,661 underlying)
  • Award

    Stock Option (right to buy)

    2021-09-14+27,746→ 27,746 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (27,746 underlying)
  • Award

    Stock Option (right to buy)

    2021-09-14+131,027→ 131,027 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (131,027 underlying)
  • Award

    Stock Option (right to buy)

    2021-09-14+88,831→ 88,831 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (88,831 underlying)
  • Award

    Stock Option (right to buy)

    2021-09-14+15,497→ 15,497 total
    Exercise: $17.00Exp: 2031-09-14→ Common Stock (15,497 underlying)
Holdings

  • Common Stock

    813,383
Footnotes (6)
  • [F1]The number of shares of Common Stock reported in the Reporting Holder's Form 3 reflected the conversion of derivative securities based on the midpoint of the Issuer's initial public offering range of $16.00 per share. The number of shares of Common Stock reflected in this Form 4 reflects the adjusted number of shares issued based on the higher initial public offering price of $17.00 per share, and does not reflect a disposition of shares.
  • [F2]Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
  • [F3]The option is fully vested and exercisable.
  • [F4]The option vests as to 1/48th of the total shares monthly, beginning October 2, 2018, subject to the Reporting Holder's continuing employment with the Registrant.
  • [F5]The option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
  • [F6]The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant.

Documents

1 file

Issuer

DICE Therapeutics, Inc.

CIK 0001645569

→
Entity typeother

Related Parties

1
  • filerCIK 0001638944

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 9:18 PM ET
Size
18.3 KB
View on SEC.gov